Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda to Prune 1,000 Jobs in US
August 5, 2024
- Alecensa Nabs Additional Nod in Earlier NSCLC Setting: Chugai
August 5, 2024
- Eisai Stands Firmly Behind Leqembi Profile despite EU Rejection
August 5, 2024
- Kyowa Kirin Pulls Plug on Stand-Alone Sales in China, Retools Asian Strategy
August 2, 2024
- Otsuka Picks Up Jnana Therapeutics for US$800 Million
August 2, 2024
- Kyowa Kirin to Offer Buyout Packages amid Research Rejig
August 2, 2024
- Otsuka’s H1 Pharma Sales Soar 18% on Rexulti, Lonsurf
August 2, 2024
- Ono Inks Fresh GPCR Antibody Pact with Monash University
August 2, 2024
- Mitsubishi Tanabe’s Buyout Program Has No Bearing on Potential Divestment: EVP
August 2, 2024
- Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
August 2, 2024
- Leqembi’s April-June Sales Up 2.2-Fold from Prior Quarter: Eisai
August 2, 2024
- Maruho, Meiji to End Co-Promotion of Amenalief in Japan
August 2, 2024
- Toa Eiyo to Downsize Workforce by 100 through Voluntary Buyout
August 1, 2024
- Sumitomo Announces Its Largest-Yet Job Cut of 700 Employees in Japan
August 1, 2024
- SanBio’s Cell Therapy Akuugo Scores Conditional Approval
August 1, 2024
- Daiichi Sankyo’s Q1 Sales Grow 24% as Mainstays Fare Well
August 1, 2024
- Chugai to Develop Roche’s PI3K Inhibitor Inavolisib in Japan
August 1, 2024
- AstraZeneca Files Tagrisso, Imfinzi for Post-Chemoradiation Setting
August 1, 2024
- Twymeeg Champion Trophy Winner in June GP Rep Promotion Rankings: Intage
August 1, 2024
- Local Anesthetic Runs Short in Japan Due to Curbed Supply of Sandoz’ Anapeine
July 31, 2024
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…